Fig. 4From: CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapyPFS (A; median follow-up was 43.7 months in patients with low NLR, and 46.8 months those with high NLR.) and OS (B; median follow-up was 52.7 months in patients with low NLR, and 51.8 months in those with high NLR.) according to rising or consistent LNR after 3 months of treatmentBack to article page